Vandetanib in Previously Treated Patients With RET-Rearranged Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lung Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final Survival Results for the LURET Phase II Study of Vandetanib in Previously Treated Patients With RET-Rearranged Advanced Non-Small Cell Lung Cancer
Lung Cancer 2021 Mar 10;155(xx)40-45, K Yoh, T Seto, M Satouchi, M Nishio, N Yamamoto, H Murakami, N Nogami, K Nosaki, T Kohno, K Tsuta, S Nomura, T Ikeno, M Wakabayashi, A Sato, S Matsumoto, K GotoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.